ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). An ADC with Co.'s proprietary technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Co. is developing IMGN632 in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia. The IMGN stock yearly return is shown above.
The yearly return on the IMGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|